Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
- DOI
- 10.1016/j.gore.2025.101796
- Published
- 2025 Aug
- Container
- Gynecologic oncology reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.gore.2025.101796,
title = {Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.},
author = {Cham S and Xiong N and Tayob N and Krasner C and Wright AA and Lee EK and Sawyer H and Mathews C and Konstantinopoulos PA and Matulonis UA and Liu JF},
year = {2025},
journal = {Gynecologic oncology reports},
doi = {10.1016/j.gore.2025.101796},
url = {https://doi.org/10.1016/j.gore.2025.101796}
}RIS
TY - JOUR TI - Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma. AU - Cham S AU - Xiong N AU - Tayob N AU - Krasner C AU - Wright AA AU - Lee EK AU - Sawyer H AU - Mathews C AU - Konstantinopoulos PA AU - Matulonis UA AU - Liu JF PY - 2025 JO - Gynecologic oncology reports DO - 10.1016/j.gore.2025.101796 UR - https://doi.org/10.1016/j.gore.2025.101796 ER -
APA
S, C., N, X., N, T., C, K., AA, W., EK, L., H, S., C, M., PA, K., UA, M., & JF, L. (2025). Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.. Gynecologic oncology reports. https://doi.org/10.1016/j.gore.2025.101796